Posted by Social Science Research Network
All Eyes on Antitrust Enforcement in China’s Pharmaceutical Industry
Adrian Emch & Jiaming Zhang (Hogan Lovells)
Abstract: A wide range of recent antitrust enforcement actions in the pharmaceutical sector have taken place in China over the past months. All three Chinese antitrust authorities have been involved, and all types of anti-competitive conduct have been targeted.
The multiple enforcement actions by a number of regulators put the pharmaceutical sector very clearly into the spotlight. Very few other sectors have seen the same level of antitrustenforcement activism in recent months in China, and there does not seem to be an end in sight to this activism.
Featured News
FTC Pushes Review of CoStar’s Commercial Real Estate Antitrust Case
Jan 31, 2024 by
CPI
UK’s CMA Investigates Ardonagh’s Atlanta Group and Markerstudy Merger
Jan 31, 2024 by
CPI
Greenberg Traurig Grow Financial Regulatory and Compliance Practice
Jan 31, 2024 by
CPI
Dutch Regulator Fines Uber €10 Million for Privacy Violations
Jan 31, 2024 by
CPI
DOJ Investigates AI Competition, Eyes Microsoft’s OpenAI Deal: Bloomberg
Jan 31, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Rule(s) of Reason
Jan 29, 2024 by
CPI
Evolving the Rule of Reason for Legacy Business Conduct
Jan 29, 2024 by
CPI
The Object Identity
Jan 29, 2024 by
CPI
In Praise of Rules-Based Antitrust
Jan 29, 2024 by
CPI
The Future of State AG Antitrust Enforcement and Federal-State Cooperation
Jan 29, 2024 by
CPI